A Nomogram Combining MRI Multisequence Radiomics and Clinical Factors for Predicting Recurrence of High-Grade Serous Ovarian Carcinoma

Table 1

Clinical and pathological characteristics of patients.

	Overall ()
	Nonrecurrence ()	Recurrence ()	value
Age (y), M (IQR)	53.0 (48.3, 60.8)	55.0 (49.0, 62.5)	0.290
CA125, M (IQR)	480.1 (220.4, 1062.3)	917.7 (564.5, 2309.0)	0.001
HE4, M (IQR)	293.5 (175.4, 589.5)	499.1 (271.2, 1059.5)	0.001
ADC value, M (IQR)	0.90 (0.77. 0.99)	0.83 (0.73, 0.92)	0.011
Fibrinogen, M (IQR)	4.17 (3.54, 4.90)	4.17 (3.22, 4.71)	0.565
NLR, M (IQR)	2.98 (2.04, 3.82)	3.05 (1.91, 4.48)	0.434
Residual tumour status, (%)			<0.001
R0	51 (39.9)	23 (34.1)
R1	25 (36.1)	42 (30.9)
Tumour location, (%)			0.211
Unilateral	36 (32.3)	24 (27.7)
Bilateral	40 (43.7)	41 (37.3)
FIGO, (%)			0.004
I-II	16 [4]	3 (8.8)
III-IV	60 (65.8)	62 (56.2)
Tumour composition, (%)			0.042
Cystic	17 (16.2)	13 (13.8)
Solid	46 (40.4)	29 (34.6)
Solid-cystic	13 (19.4)	23 (16.6)
Hemorrhage, (%)			0.880
+	10 (9.7)	8 (8.3)
-	66 (66.3)	57 (56.7)
ER, (%)			0.656
+	65 (63.6)	53 (54.4)
-	4 (5.4)	6 (4.6)
+/-	7 (7.0)	6 (6.0)
PR, (%)			0.649
+	43 (44.2)	39 (37.8)
-	26 (23.7)	18 (20.3)
+/-	7 (8.1)	8 (6.9)
PM, (%)			0.006
+	55 (61.4)	59 (52.6)
-	21 (14.6)	6 (12.4)
Primary treatment, (%)			0.023
NACT+IDS	21 (27.5)	30 (23.5)
PDS+chemotherapy	55 (48.5)	35 (41.5)
Ki-67 PI, (%)			0.629
High	61 (59.8)	50 (51.2)
Low	15 (16.2)	15 (13.8)

M: median; IQR: interquartile spacing; CA125: carbohydrate antigen 125; HE4: human epididymis protein 4; ADC: apparent diffusion coefficient; NLR: neutrophil-to-lymphocyte ratio; FIGO: International Federation of Gynecology and Obstetrics; ER: estrogen receptor; PR: progesterone receptor; PM: peritoneal metastasis; NACT: new adjuvant chemotherapy treatment; IDS: interval debulking surgery; PDS: primary debulking surgery; PI: proliferation index.